Prostate Cancer
Clinical research in metastatic castration-resistant prostate cancer focuses on treatment resistance and disease control in advanced prostate cancer.
- Metastatic castration-resistant prostate cancer
- Advanced prostate malignancy
- Androgen receptor pathway targeting
The sponsor’s activity is centered on combination treatment strategies for men with progressive disease after hormonal therapy, with attention to outcomes linked to radiographic progression-free survival.
Targeted Oncology Combinations
Research includes the pairing of gedatolisib with darolutamide, reflecting interest in combining pathway inhibition with established androgen receptor-directed therapy.
- PI3K/AKT/mTOR pathway inhibition
- Androgen receptor inhibition
- Combination anti-cancer therapy
This area addresses therapeutic resistance in mCRPC through dual-mechanism treatment approaches.
Oncology Safety and Tolerability
Clinical interest also includes the safety and tolerability of investigational oncology combinations in patients with advanced solid tumors.
- Adverse event monitoring
- Tolerability assessment
- Combination regimen safety
These studies support evaluation of treatment suitability in a population with limited options after standard hormonal therapy.
Late-Stage Disease Control
Research is directed toward controlling tumor progression in advanced prostate cancer, with emphasis on measurable disease outcomes in the metastatic setting.
- Radiographic progression-free survival
- Antitumor activity
- Metastatic disease management
The sponsor’s trial activity is concentrated on clinical endpoints relevant to patients with castration-resistant disease.
